EV/		IGINAL RESEARCH PAPER	Surgery	
		LUATION OF AUTOLOGOUS PLATELET RICH IN AS THERAPEUTIC MODALITY IN CHRONIC HEALING LEG ULCER.	<b>KEY WORDS:</b> Leg Ulcers, Prf, Wound Healing	
Dr Yogendra P Chidrawar		Junior resident, Department of surgery, Dr.Panjabrao Deshmukh medical memorial college, Amravati, Maharashtra, India.		
Dr Anil V Darokar*		Associate professor, Department of surgery, Dr.Panjabrao Deshmukh medical memorial college, Amravati, Maharashtra, India.*Corresponding Author		
Dr Bhushan J Telhure			Panjabrao Deshmukh medical	
Dr Ankur B ChawlaJunior resident, Department of orthopedics, Dr.Panjabrao Deshmukh memorial college, Amravati, Maharashtra, India.		Panjabrao Deshmukh medical		
<b>BACKGROUND:</b> Chronic leg ulcers occupy a significant number of OPD and IPD patients. Currently, Platelet Rich Fibrin (PRF) is being used in reconstructive, cosmetic and dermatologic surgery to improve tissue healing. Wound healing by application of an autologous platelet membrane is a safe, easy and inexpensive modality to treat chronic ulcers. Our aim was to study its efficacy in leg ulcers.				

**METHODS:** 24 patients with 24 ulcers were included in the study. Patients were subjected to once weekly sitting of PRFM for a period of 4 weeks and healing of the ulcer was assessed. Area and volume were calculated and photographs were taken. Final assessment of reduction in the size of the ulcer was determined in percentage

**RESULTS:** A total of 24 patients with 24 ulcers were included in the study. According to the etiology, there were 6 patients (25%)

of Hansen's disease, 5 patients (20.83%) of diabetic foot ulcer, 3 patients (12.5%) of venous ulcers, 4 patients (16.66%) of vascultis and 6 patients (25%) of traumatic ulcer. At the end of four sessions, 4 week follow-up, 1 patient (4.16%) showed reduction by 100%, 12 (50%) patients showed reduction in ulcer size by 70%, 8 (33.33%) showed reduction by 50% and 3 (12.5%) showed reduction by 30%.

**CONCLUSION:** PRFM is a safe, cost effective modality available even in small setup hospitals without requirement of many skills. Despite the various etiological factors of chronic leg ulcers, it can be very well applied in any type of ulcer without any side-effect.

## Introduction:

ABSTRACT

Chronic leg ulcers occupy a significant number of OPD and IPD patients. These patients require long follow-ups and strict sterile care of wounds. The incidence rate is 2.2 to 5.9% annually <sup>(1)</sup>. Healing of leg ulcers is a long, chronic process and is often unsatisfactory. Annual recurrence is 6 - 15 % and most ulcers recur more than once <sup>(2)</sup>. Thus, ulceration of lower limbs is a common complication of a wide spectrum of pathologies that cause a negative impact on the quality of life of patients.

Many factors need to be addressed simultaneously when treating chronic wounds, and healing often does not proceed smoothly. Under these conditions, the application of platelet- rich-derived therapies gives ground for optimism. Currently, Platelet Rich Fibrin (PRF) is being used in reconstructive, cosmetic, orthopedic, cardiovascular, oral maxillofacial and dermatologic surgery in an attempt to improve tissue healing <sup>(3)</sup>. Conventional therapies for treatment of chronic ulcers may not be always effective, require strict medical care and may in some cases need surgical correction. Hence, method of promoting wound healing by application of an autologous platelet membrane is an interesting and upcoming safe, easy and inexpensive modality to treat chronic ulcers, with no danger of allergic reactions.

Further, cost involved in the long-term management of such ulcers is substantially high. Minimizing the duration of healing can be a major step in the rehabilitation of such patients.

Recent literature shows autologous platelet rich fibrin matrix (PRFM) being rich in growth factors is effective in the treatment<sup>(4,5)</sup>.

## **Material and methods**

In the present study, we included 24 patients 24 ulcers were included in the study.

Patients who have given written consent, of the age group 18-50 www.worldwidejournals.com years, ulcer of duration of at least 6 weeks were included in the study. Patients with age of less than 18 years, history of bleeding tendency, anemia, and ulcer size of more than 5\*5cm, uncontrolled diabetics, thrombocytopenia, and malignant ulcers were excluded from the study.

### Procedure:


Ulcer size in terms of length, breadth and depth was measured. Primary infection if any was taken care using antibiotics and surgical debridement wherever necessary before starting the treatment. Under strict aseptic precautions, ten ml of venous blood was drawn and added to a sterile centrifugation tube devoid of anticoagulant. Centrifugation was done at 3000 rpm for ten minutes. Three layers were obtained following this: upper straw-coloured platelet poor plasma (PPP), red-coloured lower fraction containing red blood cells (RBCs) and the middle fraction containing the PRFM. The upper straw-coloured layer (PPP) was discarded. PRFM was separated from red corpuscles at the base using a sterile forceps and scissor, preserving a small RBC layer measuring around one mm in length, which was transferred onto sterile gauze. It was then applied on a healthy wound followed by application of a secondary non-absorbable dressing. Adequate rest was ensured during the treatment course.

The procedure was repeated every week up to a maximum of four sittings or as per requirement. At the beginning and every week, healing of the ulcer was assessed, area and volume were calculated and photographs were taken. Wound area was calculated using the formula for an ellipse: Length × width × 0.7854 (an ellipse is closer to a wound shape than a square or rectangle). The use of an ellipse for calculating wound measurement has been used in randomized controlled trials in wound healing literature <sup>(6)</sup>. Volume was calculated using the formula (length × width × 0.7854) × depth. <sup>(6)</sup> Final assessment of reduction in the size of the ulcer was determined in percentage.

3

#### **PARIPEX - INDIAN JOURNAL OF RESEARCH**

### Volume-7 | Issue-8 | August-2018 | PRINT ISSN No 2250-1991




#### **Results:**

A total of 24 patients with 24 ulcers were included in the study.

According to the etiology, there were 6 patients (25%) of Hansen's disease, 5 patients (20.83%) of diabetic foot ulcer, 3 patients (12.5%) of venous ulcers, 4 patients (16.66%) of vascultis and 6 patients (25%) of traumatic ulcer.

## Table 1: Distribution of patients according to etiology


Etiology	Number of patients
Hansen's disease	06
Traumatic ulcers	06
Diabetic foot ulcer	05
Vasculitis	04
Venous ulcer	03



# Graph 1: Distribution of patients according to etiology

Out of 24 patients, 17 were male and 7 were females.

#### Table 2: Distribution of patients according to gender




## Graph 2: Distribution of patients according to gender

Out of the 24 patients, 9 were in the age group 18-30, 10 were in the age group 31-40 years and 5 were in the age group 41-50 years. The mean age was 34.03 years.

#### Table 3: Distribution of patients according to age group

Serial No.	Age Group	Number of patients
1	18-30	09
2	31-40	10
3	41-50	05




## Graph 3: Distribution of patients according to age group

Following two sessions of PRF technique and two week follow up, 5 patients (20.83%) showed reduction in ulcer by 50%, 14 patients (58.33%) showed reduction by 30% and 5 (20.83%) showed response of 10%.

At the end of four sessions, 4 week follow-up, 1 patient (4.16%) showed reduction by 100%, 12 (50%) patients showed reduction in ulcer size by 70%, 8 (33.33%) showed reduction by 50% and 3 (12.5%) showed reduction by 30%.

### Table 4: Showing reduction in ulcer size at end of four weeks



# Graph 4: Showing reduction in ulcer size at end of four weeks

One patient who showed 100% reduction was of traumatic ulcer. Out of the 12 patients who showed reduction by 70%, 3 patients (25%) were of traumatic ulcer, 3 patients (25%) Hansen's disease, 3 patients (25%) of diabetic ulcer, 2 patients (16.66) of vasculitis and 1 patient (8.33%) of venous ulcer




#### Conclusion:

After 4 weeks Baseline

Fig. 4: Reduction on size of diabetic ulce

# Table 5: Distribution of patients showing ulcer reduction by 70% according to etiology

Etiology	Number of patients
Traumatic ulcer	03
Hansen's ulcer	03
Diabetic ulcer	03
Vasculitis	02
Venous ulcer	02



# Graph 5: Distribution of patients showing ulcer reduction by 70% according to etiology

Out of the 8 patients who showed reduction by 50%, 2 patients (25%) were of traumatic ulcer, 2 patients (25%) of Hansen's disease, 2 patients (25%) of vasculitis and 1 (12.5%) each of venous ulcer and diabetic ulcer.

Out of the 3 patients who showed reduction by less than 30% included 1 patient (33.33%) each of vasculitis, venous ulcer and diabetic ulcer.

# Discussion:

PRF first described by Choukroun et al., is a new second generation of platelet concentrate. Simplified processing technique without any complex handling makes it superior to PRP. PRF can be used to promote wound healing, bone regeneration, graft stabilization, wound sealing, and hemostasis<sup>(7)</sup>. Study by Yazawa et al. which showed that, when incorporated into drug delivery systems such as fibrin, the mean concentration of growth factors in the platelet concentrates was three times or more than that observed with conventional platelet-rich plasma. Furthermore, the growth factors were released in a controlled manner over approximately 1 week<sup>(8)</sup>

In our study maximum patients belonged to the etiological group of traumatic ulcers and Hansen's disease (25%), followed by diabetic ulcers (20.83%), vasculitis (16.66%) and venous ulcer (12.5%). The best response was found out to be in patients with traumatic ulcers and Hansen's disease. 3 patients who did not have good clinical response belonged to the group of vasculitis, diabetes and venous ulcers.Following two sessions of PRF, few patients showed reduction in size of ulcer of about 50%, indicating more number of sessions was to be required.

Only one patient showed 100% reduction in ulcer size and most patients showed reduction in 70% indicating PRF to be a good, cost effective and a satisfactory therapeutic modality for non healing ulcers.

PRFM is a safe, cost effective therapeutic modality available even in small setup hospitals without requirement of much skills. Despite the various etiological factors of chronic leg ulcers, it can be very well applied in any type of ulcer without any side-effect. However, determining the outcome of the ulcer is matter of question with multiple factors such as smoking etc. affecting the outcome.

A number of studies have been conducted to show the efficacy of PRF in chronic non healing ulcers. Most studies show that patients have complete clinical resolution at the end of studies at around 6 to 8 weeks. Our study shows that PRF does help in clinical resolution but it has more roles in augmenting the healing at the same time.

As seen in our study, similar result has been obtained in other studies. In a study by nagaraju et al., a complete closure of all ulcers was achieved in a maximum of 5 weeks<sup>(9)</sup>.

In a study by Sarvajnamurthy et al. mean duration of the healing of the chronic venous ulcers using PRP was in 5.1 weeks.<sup>(1)</sup>

## Acknowledgement: none

### Conflict of interest: none

### Funding: none

#### References

- Birgit K, Hans-Joachim H, Georg Gallenkemper, Evidence-Based Treatment of
- Chronic Leg Ulcers; Dtsch Arztebi Int. 2011 April; 108(14): 231–237. Tony B, Stephen B, Neil Cox, Christopher G, editors. Rook's textbook of dermatology. Eighth edition. West Sussex. Wiley-Blackwell; 2010. 2)
- David M. Dohan, Joseph Choukroun, Antoine Diss, Steve L. Dohan, Anthony J. J. Dohan, Jaafar Mouhyi, Bruno Gogly, Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution; Oral Surg Oral 3)
- Med Oral Pathol Oral Radiol Endod 2006 Mar; 101 (3): e37-44. Epub 2006 Jan 19. O'Connell SM, Hessler K, Dardik H. Cascade \* autologous system platelet-rich fibrin matrix in the treatment of chronic leg ulcers. Adv Wound Care (New Rochelle) 4) 2012;1:52-55.
- Steenvoorde P, van Doorn LP, Naves C, Oskam J. Use of autologous Platelet rich fibrin on hard to heal wounds. J Wound Care 2008;17:60-3. 5)
- Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure 6) wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: A multicenter randomized controlled trial. Diabetes Care 2008;31:631-6.
- Balaram Naik, P Karunakar, 1 M Jayadev, 1 and V Rahul Marshal2. Role of Platelet rich fibrin in wound healing: A critical review J Conserv Dent. 2013 Jul-Aug; 16(4): 7): 284-293
- 8) Yazawa M, Ogata H, Nakajima T, Mori T, Watanabe N, Handa M. Basic studies on the clinical applications of platelet-rich plasma. Cell Transplant 2003;12:509-18.
- 9) Suchetha A, Lakshmi P, Bhat D, Mundinamane DB, Soorya KV, Bharwani GA Platelet concentration in platelet concentrates and periodontal regenerationunscrambling the ambiguity. Contemp Clin Dent 2015; 6:510-6.
- Sarvajnamurthy S, Suryanarayan S, Budamakuntala L, Suresh DH. Autologous platelet rich plasma in chronic venous ulcers: Study of 17 cases. J Cutan Aesthet 10) . Surg 2013;6:97-9.